Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini oral session - CNS tumours

344MO - Experience of GEINO (Spanish cooperative group for research in neuro-oncology) oncologists in the management of adult medulloblastoma


20 Sep 2021


Mini oral session - CNS tumours


Tumour Site

Central Nervous System Malignancies


Maria Vieito Villar


Annals of Oncology (2021) 32 (suppl_5): S516-S529. 10.1016/annonc/annonc674


M. Vieito Villar1, R. Luque Caro2, M.C. Martin Soberon3, A. Herrero Ibañez4, R. Girones Sarrio5, N. Luque Caro6, M. Alonso Garcia7, T. Quintanar Verduguez8, S. del Barco Berrón9, I. Moya Horno10, M.T. Tuñón Cabeza11, O. Gallego12, R. de las Peñas13, M.Á. Vaz Salgado14, I. CEBALLOS LENZA15, A.J. Cunquero-Tomás16, S. Peralta Muñoz17, M. Gutierrez Toribio18, J. Diaz Santos19

Author affiliations

  • 1 Medical Oncology Dept., Vall d'Hebron University Hospital, 8035 - Barcelona/ES
  • 2 Medical Oncology Dept., HOSPITAL VIRGEN DE LAS NIEVES, Granada/ES
  • 3 Medical Oncology Dept., Hospital 12 de Octubre, 0000 - Madrid/ES
  • 4 Oncology, Hospital Miguel Servet, 50009 - Zaragoza/ES
  • 5 Hospital Universitari I Politècnic La Fe Valencia, Hospital Universitari i Politècnic La Fe - IIS La Fe - Instituto de Investigación Sanitaria La Fe, 46026 - Valencia/ES
  • 6 Medical Oncology, Hospital de Jaén, 0000 - Jaén/ES
  • 7 Medical Oncology Dept., Hospital Universitario Virgen del Rocio de Sevilla, 0000 - Sevilla/ES
  • 8 Medical Oncology, Hospital General Universitario de Elche, 03203 - Elche/ES
  • 9 Medical Oncology Dept., Hospital Universitari Dr. Josep Trueta. ICO Girona, 0000 - Girona/ES
  • 10 Medical Oncology Dept., Instituto Oncologico Dr. Rosell, 8028 - Barcelona/ES
  • 11 Medical Oncology Dept., C.H. Navarra, 0000 - Pamplona/ES
  • 12 Medical Oncology Dept., Hospital de Sant Pau i La Santa Creu, 0000 - Barcelona/ES
  • 13 Medical Oncology Dept., Hospital provincial de Castellón, 0000 - Castellón/ES
  • 14 Medical Oncology Dept., Hospital Universitario Ramon y Cajal, 28031 - Madrid/ES
  • 15 Oncologia Medica, Hospital Universitario de Canarias, 38320 - San Cristobal de la Laguna/ES
  • 16 Medical Oncology, Consorcio Hospital General Universitario de Valencia, 46014 - Valencia/ES
  • 17 Medical Oncology Dept., Hospital Universitari Sant Joan de Reus, 43204 - Reus/ES
  • 18 Medical Oncology Dept., H Áraba, 0000 - Araba/ES
  • 19 Medical Oncology Dept., UGC Intercentros de Oncología Médica. Hospitales Universitarios Regional y Virgen de la Victoria Málaga, IBIMA, 0000 - Malaga/ES


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 344MO


Medulloblastoma (MB) is extremely rare in adults (1% of CNS tumors). Comparative studies show important biological differences between adult and pediatric patients with implications in clinical behaviour and patient outcomes. Although MB is potentially curable with a multidisciplinary approach comprising a combination of maximal safe resection, craniospinal irradiation (CSI), and chemotherapy (CT), the lack of specific studies in the adult subpopulation forces oncologist to adapt treatment regimens.


GEINO Neuro-oncologists were asked to register MB patients in the GEINO-GETHI National CNS tumor register (pts alive at the time of inclusion gave informed consent).


Between 1996 and 2021, 71pts either diagnosed as adults (median age 32y range 18-71) or referred to adult units (7pts), were identified. 42% were female, common symptoms included headache (69%) and ataxia (31%). Of 14 pts with molecular classification, 10 were SHH+(1 pt p53 mutated) and the others non-WNT non-SHH+ and of 23 patients with histological subtype 19 were desmoplasic-nodular. 70,6% underwent complete resection, 23,5 partial and 5,9 biopsy. 95% received radiotherapy, most commonly to the tumor (61%) with a median dose of 55Gy and to the neuroaxis (48%) with a median dose of 36 Gy. Diverse treatment strategies were used: sequential chemotherapy 42.9% (of wich 29% Vincristine-lomustine-platin), 19% concomitant and sequential (80%concomitant vincristine followed in 50% by Vincristine-lomustine-platin), 14% only concomitant CT (66% with vincristine) 7.9% only neoadjuvant(80% carboplatin-VP16, followed in 40% by the same schema) and 7.9% only CT(66% with a platin-VP16 triplet). Median survival was 14,37y and 70.1% remain relapse free.


Significant heterogeneity is present in the management of adult MB in Spain. Although treatment in MB should be individualized and treatment outcomes are in line with published series, differences in treatment schemas and availability of molecular diagnostic tools highlight the importance of collaborative groups to standardize management.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study





All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.